open access

Vol 23, No 4 (2018)
Original research articles
Published online: 2018-07-01
Submitted: 2018-01-17
Get Citation

Acute toxicity and quality of life in high risk prostate cancer patients: Updated results of randomized hypofractionation trial

Agata Karklelyte, Konstantinas Povilas Valuckas, Romas Griskevicius, Ernestas Janulionis, Eduardas Aleknavicius
DOI: 10.1016/j.rpor.2018.06.008
·
Rep Pract Oncol Radiother 2018;23(4):284-289.

open access

Vol 23, No 4 (2018)
Original research articles
Published online: 2018-07-01
Submitted: 2018-01-17

Abstract

Purpose

The aim of our study was to perform the final analysis of acute toxicity and quality of life data obtained from 221 consecutive patients who suffered from intermediate-to-high risk prostate cancer.

Methods

In this trial, 221 patients were randomized to receive either hypofractionated (63 Gy in 20 fractions, 4 fractions/week) or conventionally fractionated (76 Gy in 38 fractions, 5 fractions/week) radiotherapy to the prostate and seminal vesicles. Elective pelvic lymph node irradiation with 46 Gy in 23 fractions sequentially and 44 Gy in 20 fractions simultaneously was also applied.

Results

There was no statistically significant difference in acute GU and GI toxicity in men treated with hypofractionated (SIB) (Arm 2) in comparison with patients who had conventional fractionation (Arm 1) radiation therapy. Multivariate analysis using logistic regression showed statistical significant association between acute GU ≥ 1 and PTV(LN) (p = 0.008) only. We found out that clinically relevant decrease (CRD) was significantly higher only in the urinary domain of Arm 1 at month 3 (p = 0.02).

Conclusion

Our study demonstrated that hypofractionated radiotherapy was associated with a small but insignificant increase of acute toxicity. The reduction of overall treatment time has no significant influence on patients’ QOL in any domain.

Abstract

Purpose

The aim of our study was to perform the final analysis of acute toxicity and quality of life data obtained from 221 consecutive patients who suffered from intermediate-to-high risk prostate cancer.

Methods

In this trial, 221 patients were randomized to receive either hypofractionated (63 Gy in 20 fractions, 4 fractions/week) or conventionally fractionated (76 Gy in 38 fractions, 5 fractions/week) radiotherapy to the prostate and seminal vesicles. Elective pelvic lymph node irradiation with 46 Gy in 23 fractions sequentially and 44 Gy in 20 fractions simultaneously was also applied.

Results

There was no statistically significant difference in acute GU and GI toxicity in men treated with hypofractionated (SIB) (Arm 2) in comparison with patients who had conventional fractionation (Arm 1) radiation therapy. Multivariate analysis using logistic regression showed statistical significant association between acute GU ≥ 1 and PTV(LN) (p = 0.008) only. We found out that clinically relevant decrease (CRD) was significantly higher only in the urinary domain of Arm 1 at month 3 (p = 0.02).

Conclusion

Our study demonstrated that hypofractionated radiotherapy was associated with a small but insignificant increase of acute toxicity. The reduction of overall treatment time has no significant influence on patients’ QOL in any domain.

Get Citation

Keywords

Prostate cancer; Hypofractionation; Acute toxicity; Radiotherapy; Quality of life

About this article
Title

Acute toxicity and quality of life in high risk prostate cancer patients: Updated results of randomized hypofractionation trial

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 23, No 4 (2018)

Pages

284-289

Published online

2018-07-01

DOI

10.1016/j.rpor.2018.06.008

Bibliographic record

Rep Pract Oncol Radiother 2018;23(4):284-289.

Keywords

Prostate cancer
Hypofractionation
Acute toxicity
Radiotherapy
Quality of life

Authors

Agata Karklelyte
Konstantinas Povilas Valuckas
Romas Griskevicius
Ernestas Janulionis
Eduardas Aleknavicius

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl